Literature DB >> 631480

Macrophage turnover in Crohn's disease and ulcerative colitis.

G Meuret, A Bitzi, B Hammer.   

Abstract

Monocytopoietic proliferation activity was determined in 8 patients during severe attacks of Crohn's disease and in 6 patients with ulcerative colitis. Similar results were obtained in both groups of patients. A moderate but significant hyperproliferation of monocytopoiesis was found to be present in about half of the patients, and with some of the remainder of cases, part of the criteria for hyperproliferation were also fulfilled. This indicates that Crohn's disease as well as ulcerative colitis are frequently associated with moderate overproduction of monocytes which may be assumed to be induced by macrophage demand of the affected tissues. In comparison with other diseases involving inflammations, the monocytopoietic hyperproliferation was moderate. Therefore, the inflammation in Crohn's disease and ulcerative colitis seems to be characterized by a relatively low macrophage turnover induced by pathogenetic mechanisms of moderate macrophage toxicity.

Entities:  

Mesh:

Year:  1978        PMID: 631480

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

1.  Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study.

Authors:  Ken Fukunaga; Kazuko Nagase; Takeshi Kusaka; Nobuyuki Hida; Yoshio Ohda; Koji Yoshida; Katsuyuki Tozawa; Koji Kamikozuru; M Iimuro; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

2.  Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.

Authors:  Koji Sawada; Akimitsu Egashira; Kunio Ohnishi; Ken Fukunaga; Takeshi Kusaka; Takashi Shimoyama
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

3.  Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Authors:  V Muratov; J Lundahl; A K Ulfgren; K Elvin; I Fehrman; N Ahlborg; A Ost; N Hittel; A Saniabadi; R Löfberg
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

Review 4.  Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.

Authors:  Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

5.  Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Takayuki Iida; Masami Yamada; Yoshihiko Sato; Ken Takeuchi; Tatsuo Tanaka; Kenji Kondo; Masataka Kikuyama; Yasuhiko Maruyama; Yasushi Iwaoka; Akiko Nakamura; Kazuhisa Hirayama; Abby R Saniabadi; Fumitoshi Watanabe
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

6.  Interleukin 2 receptor expression by macrophages in inflammatory bowel disease.

Authors:  Y R Mahida; S Patel; K Wu; D P Jewell
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

7.  Increased suppressor cell activity in inflammatory bowel disease.

Authors:  G Holdstock; B F Chastenay; E L Krawitt
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

8.  Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease.

Authors:  Y R Mahida; K C Wu; D P Jewell
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

9.  Immune status in Crohn's disease. 4. In vitro antibody dependent cell mediated cytotoxicity in peripheral blood.

Authors:  I O Auer; E Ziemer
Journal:  Klin Wochenschr       Date:  1980-08-01

10.  Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease.

Authors:  K R Gardiner; A D Crockard; M I Halliday; B J Rowlands
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.